BioSpace News Archive

Harvest Health & Recreation Inc. (CSE: HARV, OTCQX: HRVSF) (“Harvest”), a vertically integrated cannabis company with one of the largest and deepest footprints in the U.S., today announced that it will hold a conference call on Tuesday, April 7, 2020 at 5:00 PM Eastern Time following the release of its fourth quarter 2019 financial results.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Company has completed the submission of its Biologics License Application (“BLA”) under the FDA’s Rolling Review process for naxitamab after market close on March 31, 2020. Naxitamab is

International Pharmaceutical Veteran to Lead Global Business and Commercial Development

- The Ontario Superior Court of Justice has approved a settlement in a Canadian class action lawsuit related to certain defibrillators manufactured before December 31, 2003 by Medtronic, Inc. and/or Medtronic of Canada Ltd. The Settlement provides for the creation of a $3.072 million CDN settlement fund which will be used to pay compensation

NOCD, a telehealth company that specializes in identifying and treating people with obsessive-compulsive disorder (OCD), today reported that therapy sessions on its platform have more than doubled since the start of the COVID-19 outbreak in early March.

FibroGenesis, a Texas-based regenerative medicine company focused on tissue regeneration and chronic disease reversal using Human Dermal Fibroblasts (HDFs), today announced the filing of United States Provisional Patent Number 63/002,134 titled, “Peptides and Adjuvants for Augmentation of Fibroblast Therapy for Coronavirus.”

The German government is readying a massive cash injection to help innovative young companies ride out economic difficulties.

The World House has called on U.S. health regulators to expedite potential therapies aimed at treating COVID-19 amid the fast-spreading coronavirus outbreak, saying it could lead to a breakthrough while a vaccine is still under development.

Individuals with the rare disease sarcoidosis live with concerns about their vulnerable health. The novel coronavirus disease, COVID-19, presents new risk and uncertainty for those with compromised immune systems.

Immunovia AB (publ) (“Immunovia”) today provides an update on the actions that the company is taking to support patients, employees, and public health initiatives in response to the coronavirus (COVID-19) pandemic. Despite these extraordinary times, Immunovia remains focused on the Q3 2020 sales start for the first test for early dia